|
DE69434475T2
(de)
*
|
1993-08-11 |
2006-05-18 |
Jenner Technologies, Tiburon |
Impfstoff gegen prostatakrebs
|
|
US20010036928A1
(en)
*
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
CN1298851C
(zh)
*
|
1998-11-18 |
2007-02-07 |
牛津生物医学（英国）有限公司 |
多肽
|
|
JP4409097B2
(ja)
*
|
1998-12-09 |
2010-02-03 |
アメリカ合衆国 |
複数の共刺激分子を発現する組換えベクターおよびその利用
|
|
EP1865065A1
(en)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
PT1496939E
(pt)
*
|
2002-04-09 |
2007-11-22 |
Sanofi Pasteur Ltd |
''ácido nucleico de cea modificado e vectores de expressão''
|
|
CA2536317A1
(en)
*
|
2003-08-21 |
2005-03-03 |
Virax Development Pty Ltd |
Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
|
|
DE602004032365D1
(de)
*
|
2003-10-08 |
2011-06-01 |
Sanofi Pasteur Inc |
Modifizierter cea/b7-vektor
|
|
EP1687322B1
(en)
|
2003-11-12 |
2017-02-08 |
The Government of the United States of America, represented by the Secretary, Department of Health and Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
JP4995575B2
(ja)
*
|
2003-11-12 |
2012-08-08 |
アメリカ合衆国 |
乳癌を処置および予防するためのシステム
|
|
US20110287089A1
(en)
|
2009-01-13 |
2011-11-24 |
Karola Rittner |
Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
|
|
PT2382474E
(pt)
|
2009-01-20 |
2015-06-03 |
Transgene Sa |
Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
|
|
AU2010227611B2
(en)
|
2009-03-24 |
2014-05-29 |
Transgene Sa |
Biomarker for monitoring patients
|
|
AU2010237215B2
(en)
|
2009-04-17 |
2014-05-01 |
Transgene Sa |
Biomarker for monitoring patients
|
|
US9261512B2
(en)
|
2009-07-10 |
2016-02-16 |
Transgene, S.A. |
Biomarker for treating cancer patients
|
|
US9804163B2
(en)
|
2010-08-06 |
2017-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for prostate cancer and methods for their detection
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
EP3065770B1
(en)
*
|
2013-11-05 |
2020-10-28 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of an immune checkpoint inhibitor
|
|
EP3142689B1
(en)
|
2014-05-13 |
2020-11-11 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
|
|
AU2015289081B2
(en)
|
2014-07-16 |
2020-02-06 |
Transgene Sa |
Combination of oncolytic virus with immune checkpoint modulators
|
|
CN107949397A
(zh)
|
2015-02-13 |
2018-04-20 |
特兰斯吉恩股份有限公司 |
免疫治疗疫苗和抗体组合治疗
|
|
IL256869B
(en)
|
2015-07-31 |
2022-07-01 |
Bavarian Nordic As |
promoters for increased expression in poxviruses
|
|
EP3400009A2
(en)
|
2016-01-05 |
2018-11-14 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
ES2924741T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
WO2018060368A2
(en)
|
2016-09-28 |
2018-04-05 |
Bavarian Nordic A/S |
Compositions and methods for enhancing the stability of transgenes in poxviruses
|
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
AU2017387549B2
(en)
|
2016-12-28 |
2023-07-06 |
Transgene Sa |
Oncolytic viruses and therapeutic molecules
|
|
CA3058966A1
(en)
|
2017-04-14 |
2018-10-18 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
JP2020519666A
(ja)
|
2017-05-15 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
安定性のウイルス含有組成物
|
|
EP3624845A1
(en)
|
2017-05-15 |
2020-03-25 |
Janssen Vaccines & Prevention B.V. |
Stable virus-containing composition
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
MX2020001856A
(es)
|
2017-08-24 |
2020-07-13 |
Bavarian Nordic As |
Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo.
|
|
MX2020009262A
(es)
|
2018-03-07 |
2021-01-08 |
Transgene |
Vectores de parapoxvirus.
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
EP3847246A1
(en)
|
2018-09-06 |
2021-07-14 |
Bavarian Nordic A/S |
Storage improved poxvirus compositions
|
|
US20220233607A1
(en)
|
2019-05-29 |
2022-07-28 |
Université De Tours |
Toxoplasma platform for treating cancer
|
|
AU2021226023A1
(en)
|
2020-02-28 |
2022-09-15 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
|
MX2022011071A
(es)
|
2020-03-12 |
2022-09-23 |
Bavarian Nordic As |
Composiciones que mejoran la estabilidad del poxvirus.
|
|
WO2024038175A1
(en)
|
2022-08-18 |
2024-02-22 |
Transgene |
Chimeric poxviruses
|